Can The COVID Approach Be Used For Other Therapeutics? FDA Speed Is Factor, Pfizer’s Bourla Says

Execs debate how to achieve COVID-fast development of all products; challenges include reforming corporate bureaucracies and getting regulators more funding. Regeneron’s Schleifer says trouble distributing its monoclonal antibodies stemmed from government’s ‘maniacal focus on vaccines.’

COVID speed
Pharma execs note challenges in applying COVID-19 lessons to future therapeutics • Source: Alamy

More from Vaccines

More from Pink Sheet